Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361951381> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4361951381 abstract "<div>Abstract<p><b>Purpose:</b> Integrins play a critical role in the progression of prostate cancer and its bone metastases. We investigated the use of the pan-αv integrin inhibitor abituzumab in chemotherapy-naïve patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.</p><p><b>Experimental Design:</b> PERSEUS (NCT01360840) was a randomized, double-blind phase II study. Men with pathologically confirmed prostate cancer and radiologic progression of bone lesions in the 28 days prior to randomization were assigned to receive abituzumab 750 mg or 1,500 mg or placebo (1:1:1) every 3 weeks in combination with luteinizing hormone-releasing hormone agonist/antagonist therapy. The primary endpoint was progression-free survival (PFS).</p><p><b>Results:</b> The intent-to-treat population comprised 180 patients, 60 in each arm. The primary endpoint of PFS was not significantly different with abituzumab-based therapy compared with placebo [abituzumab 750 mg, 3.4 months, HR = 0.89; 95% confidence interval (CI), 0.57–1.39; abituzumab 1,500 mg, 4.3 months, HR = 0.81; 95% CI, 0.52–1.26; placebo, 3.3 months], but the cumulative incidence of bone lesion progression was lower with abituzumab than with placebo for up to 24 months (cumulative incidence 23.6% vs. 41.1% at 6 months, 26.1% vs. 45.4% at 12 months). Two partial tumor responses were observed (1 abituzumab 1,500 mg and 1 placebo). Approximately 85% to 90% of patients experienced at least one treatment-emergent adverse event (TEAE) in the different arms, but the incidences of serious TEAEs and TEAEs with fatal outcome were similar in the three arms.</p><p><b>Conclusions:</b> Although PFS was not significantly extended, abituzumab appears to have specific activity in prostate cancer–associated bone lesions that warrants further investigation. <i>Clin Cancer Res; 22(13); 3192–200. ©2016 AACR</i>.</p></div>" @default.
- W4361951381 created "2023-04-05" @default.
- W4361951381 creator A5000710774 @default.
- W4361951381 creator A5009585365 @default.
- W4361951381 creator A5023705054 @default.
- W4361951381 creator A5041126882 @default.
- W4361951381 creator A5055627152 @default.
- W4361951381 creator A5070258271 @default.
- W4361951381 date "2023-03-31" @default.
- W4361951381 modified "2023-10-04" @default.
- W4361951381 title "Data from Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer" @default.
- W4361951381 doi "https://doi.org/10.1158/1078-0432.c.6523109.v1" @default.
- W4361951381 hasPublicationYear "2023" @default.
- W4361951381 type Work @default.
- W4361951381 citedByCount "0" @default.
- W4361951381 crossrefType "posted-content" @default.
- W4361951381 hasAuthorship W4361951381A5000710774 @default.
- W4361951381 hasAuthorship W4361951381A5009585365 @default.
- W4361951381 hasAuthorship W4361951381A5023705054 @default.
- W4361951381 hasAuthorship W4361951381A5041126882 @default.
- W4361951381 hasAuthorship W4361951381A5055627152 @default.
- W4361951381 hasAuthorship W4361951381A5070258271 @default.
- W4361951381 hasBestOaLocation W43619513812 @default.
- W4361951381 hasConcept C121608353 @default.
- W4361951381 hasConcept C126322002 @default.
- W4361951381 hasConcept C126894567 @default.
- W4361951381 hasConcept C142724271 @default.
- W4361951381 hasConcept C143998085 @default.
- W4361951381 hasConcept C168563851 @default.
- W4361951381 hasConcept C203092338 @default.
- W4361951381 hasConcept C204787440 @default.
- W4361951381 hasConcept C27081682 @default.
- W4361951381 hasConcept C2780192828 @default.
- W4361951381 hasConcept C2908647359 @default.
- W4361951381 hasConcept C2911091166 @default.
- W4361951381 hasConcept C71924100 @default.
- W4361951381 hasConcept C88879693 @default.
- W4361951381 hasConcept C90924648 @default.
- W4361951381 hasConcept C99454951 @default.
- W4361951381 hasConceptScore W4361951381C121608353 @default.
- W4361951381 hasConceptScore W4361951381C126322002 @default.
- W4361951381 hasConceptScore W4361951381C126894567 @default.
- W4361951381 hasConceptScore W4361951381C142724271 @default.
- W4361951381 hasConceptScore W4361951381C143998085 @default.
- W4361951381 hasConceptScore W4361951381C168563851 @default.
- W4361951381 hasConceptScore W4361951381C203092338 @default.
- W4361951381 hasConceptScore W4361951381C204787440 @default.
- W4361951381 hasConceptScore W4361951381C27081682 @default.
- W4361951381 hasConceptScore W4361951381C2780192828 @default.
- W4361951381 hasConceptScore W4361951381C2908647359 @default.
- W4361951381 hasConceptScore W4361951381C2911091166 @default.
- W4361951381 hasConceptScore W4361951381C71924100 @default.
- W4361951381 hasConceptScore W4361951381C88879693 @default.
- W4361951381 hasConceptScore W4361951381C90924648 @default.
- W4361951381 hasConceptScore W4361951381C99454951 @default.
- W4361951381 hasLocation W43619513811 @default.
- W4361951381 hasLocation W43619513812 @default.
- W4361951381 hasOpenAccess W4361951381 @default.
- W4361951381 hasPrimaryLocation W43619513811 @default.
- W4361951381 hasRelatedWork W2014119546 @default.
- W4361951381 hasRelatedWork W2120584068 @default.
- W4361951381 hasRelatedWork W2392413698 @default.
- W4361951381 hasRelatedWork W3159250744 @default.
- W4361951381 hasRelatedWork W4230120862 @default.
- W4361951381 hasRelatedWork W4256514411 @default.
- W4361951381 hasRelatedWork W4285099082 @default.
- W4361951381 hasRelatedWork W4292236216 @default.
- W4361951381 hasRelatedWork W4312225894 @default.
- W4361951381 hasRelatedWork W2083697902 @default.
- W4361951381 isParatext "false" @default.
- W4361951381 isRetracted "false" @default.
- W4361951381 workType "article" @default.